A group of scientists from the Angiogenesis Unit of the Biomedical Research Centre of La Rioja (CIBIR) has succeeded in creating a vaccine, based on messenger RNA technology, that ...

High dietary inflammatory index (DII), which quantifies the inflammatory potential of diet, is associated with increased ...

A large-scale bibliometric analysis maps global research on hydrogels as next-generation drug delivery systems for cancer ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--IncellDx, a precision medicine company, today announced the journal Frontiers in Immunology has published a study detailing a framework for understanding the ...

"Eleva commences Phase I clinical trial for C3G treatment" was originally created and published by Clinical Trials Arena, a ...

Approximately 40% of the European population are allergic to pollen, and their symptoms cause an estimated loss of 100 ...

A common hay fever trigger could be treated by placing a "molecular shield" in the nose within five years. Scientists have ...

Researchers developed a nasal antibody that blocks mugwort pollen, a major hay fever trigger in Europe and Central Asia.

--Indaptus Therapeutics, Inc., a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announced today that Dr. Michael Newman, Founder and ...

Frontiers in Immunology, 2023; 14 DOI: 10.3389/fimmu.2023.1228532; Cite This Page: MLA; APA; Chicago; University of Massachusetts Amherst. "Can immunity from routine vaccines be used to fight ...

Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology.